EEG global field power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers

Brain Topography

Volumn 16, Issue 4, 2004, Pages 281-285

  Yamada, Keizo ^a   Isotani, Toshiaki ^a   Irisawa, Satoshi ^a   Yoshimura, Masafumi ^a   Tajika, Aran ^a   Yagyu, Takami ^a   Saito, Akemi ^a   Kinoshita, Toshihiko ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Global Field Power; LORETA (Low Resolution Electromagnetic Tomography); Multi channel EEG; Olanzapine; Perospirone; Quantitative pharmaco EEG; Quetiapine; Risperidone

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE;

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN MAPPING; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; SPECTRUM ANALYSIS; TIME FACTORS;

EID: 3342983221     PISSN: 08960267     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BRAT.0000032866.20058.5c     Document Type: Article

References (17)

1. Galderisi, S., Mucci, A., Bucci, P., Mignone, M.L. and Maj, M. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Res., 1996, 67:113-122.
2. Goldstein, J.M. Atypical antipsychotic drugs: beyond acute psychosis, new directions. Emerging Drugs, 1999, 4: 127-151.
3. Hughes, A.M., Lynch, P., Rhodes, J., Ervine, C.M. and Yates, R.A. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br. J. Clin. Pharmacol., 1999, 48: 323-330.
4. Hubl, D., Kleinlogel, H., Frolich, L., Weinandi, T., Maurer, K., Holstein, W., Czekalla, J. and Dierks, T. Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine. Psychopharmacol., 2001, 158: 281-288.
5. Kando, J.C., Shepski, J.C., Satterlee, W., Patel, J.K., Reams, S.G. and Green, A.I. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann. Pharmacother., 1997, 31: 1325-1334.
6. Kane, J.M., Leucht, S., Carpenter, D. and Docherty, J.P. Optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry, 2003, 64: 58.
7. Kubicki, S., Herrmann, W.M., Fichte, K. and Freund, G. Reflections on the topics: EEG frequency bands and regulation of vigilance. Pharmakopsychiatr. Neuropsychopharmacol., 1979, 12: 237-245.
8. Lee, D.Y., Lee, K.U., Kwon, J.S., Jang, I.J., Cho, M.J., Shin, S.G. and Woo, J.I. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology, 1999, 144: 272-278.
9. Lehmann, D. and Skrandies, W. Reference-free identification of components of checkerboard evoked multichannel potential fields. Electroenceph. Clin. Neurophysiol., 1980, 48: 609-621.
10. Morokawa, Y. Clinical effects of novel antipsychotics - The comparison of phase III trials -. Jap. J. Clinical Psychopharmacology, 2002, 5: 1391-1404.
11. Pascual-Marqui, R.D., Lehmann, D., Koenig, T., Kochi, K., Merlo, M.C.G., Hell, D. and Koukkou, M. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naïve, first-episode, productive schizophrenia. Psychiatry Res. Neuroimaging, 1999, 90: 169-179.
12. Roubicek, J. and Major, I. EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol. Psychiatry, 1977, 12: 613-633.
13. Saito, A., Kuginuki, T., Fukushima, M. and Saito, M. Pharmaco-EEG Study of perospirone, a D2 and 5-HT2 antagonist, in healthy male volunteers. Noha To Kindenzu, 1998, 26: 205-215.
14. Saito, M., Kagono, Y., Suitsu, N., Yamamoto, Y., Kinoshita, T., Ohya, D., Fukui, Y. and Hashimoto, C. A study on anti-psychotic drugs by the aid of quantitative EEG and multivariate analysis. - doses and action trait of haloperidol. Jpn. J. Neuropsychopharmacol., 1983, 5: 843-856.
15. Saito, N., Okajima, Y., Isotani, T., Yagyu, T., Nobuhara, K., Nishimura, T., Fukushima, M., Kuginuki, T., Kinoshita, T. and Saito, M. Early prediction and orientation of the clinical effects of a new antipsychotic compound, risperidone, in human: a quantitative pharmaco-EEG study. Jpn. J. Neuropsychopharmacol., 1993, 15: 693-703.
16. Saletu, B., Grünberger, J., Linzmayer, L. and Anderer, P. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Pharmacopsychiatry, 1987, 20: 12-27.
17. Small, J.G., Milstein, V., Malloy, F.W. and Miller, M.J. Quantitative electroencephalographic frequencies and relative neuroleptic receptor affinities in schizophrenia. Biol. Psychiatry, 1996, 39: 986-988.